Reviva Pharmaceuticals Holdings (RVPH) AI Stock Analysis

• Market Cap: $41.60M
• Dividend Yield: N/A
• Average Volume (3M): 794.81K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.88
• Revenue Growth: N/A
• EPS Growth: 45.15%
• Country: US
• Employees: 14
• Sector: Healthcare
• Sector Strength: 74
• Industry: Biotechnology
• EPS (TTM): -0.90
• Shares Outstanding: 46,739,950
• 10 Day Avg. Volume: 447,726
• 30 Day Avg. Volume: 794,808
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 1.51
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $11.25
• Price Target Upside: 1164.04% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5

Reviva Pharmaceuticals Holdings faces significant financial challenges, with zero revenue, substantial net losses, and negative cash flows, heavily weighing down its stock score. The technical analysis indicates weak momentum and a downward trend, while the negative P/E ratio and lack of dividends reflect poor valuation. Recent corporate events show leadership confidence but do not mitigate the underlying financial distress.

Positive Factors

Drug Development and Efficacy

Brilaroxazine has shown positive Phase 3 data demonstrating its impact on positive, negative, and cognition symptoms in schizophrenia patients with an effect size greater than many antipsychotics.

Market Position and Valuation

Reviva looks extremely undervalued relative to Intra-Cellular's $14.6B price tag, highlighting potential for stock appreciation.

Negative Factors

Financial Needs

The company will likely need additional capital in order to move its clinical programs forward.

Valuation Discrepancy

Acquisition of rival for massive premium serves to emphasize significant unwarranted valuation discrepancy.

Reviva Pharmaceuticals Holdings Business Overview & Revenue Model

Company Description

Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is RP5063, which is in Phase III clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attention–deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company is headquartered in Cupertino, California.

How the Company Makes Money

Reviva Pharmaceuticals Holdings generates revenue primarily through the development and commercialization of its drug candidates. The company relies on funding from partnerships, collaborations, and potential licensing agreements with larger pharmaceutical companies. These partnerships may include milestone payments and royalties based on the successful development and commercialization of its products. Additionally, Reviva may receive grants or research funding from governmental or non-governmental organizations to support its drug development programs. As a clinical-stage company, its revenue generation is heavily dependent on the successful advancement of its pipeline through clinical trials and achieving regulatory approvals.

Reviva Pharmaceuticals Holdings Financial Statement Overview

Summary

Reviva Pharmaceuticals Holdings' financial performance reflects challenges typical of early-stage biotech firms. With no revenue and substantial losses, the company shows negative equity and consistent cash burn, relying heavily on external financing.

Income Statement

Reviva Pharmaceuticals Holdings has reported no revenue over the observed periods, which is typical for early-stage biotechnology firms focused on R&D. However, substantial and increasing net losses pose a significant concern, with a TTM net income of -$33.38 million. The absence of revenue growth and negative profit margins highlight the high-risk nature of the company's current financial position.

Balance Sheet

The company's balance sheet reveals a negative stockholders' equity in the TTM period at -$9.98 million, indicating insolvency. Additionally, despite having minimal debt, the high total liabilities relative to assets and negative equity ratio suggest financial instability and potential liquidity issues.

Cash Flow

Reviva Pharmaceuticals Holdings has consistently negative free cash flow, with a TTM free cash flow of -$33.32 million. This trend reflects ongoing cash burn typical in biotech companies without product revenue. The company's reliance on financing activities to support operations further underscores the financial risk.

Breakdown
Dec 2023	Dec 2022	Dec 2021	Dec 2020	Mar 2020
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00
	Gross Profit
0.00	0.00	0.00	-724.74K	0.00
	EBIT
-39.50T	-24.31M	-10.10M	-2.43M	-376.86K
	EBITDA
-39.50T	-24.11M	-10.10M	-2.33M	-376.01K
	Net Income Common Stockholders
-39.26T	-24.34M	-8.52M	-3.78M	-846.83K
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
23.37M	18.52M	29.69M	8.76M	193.00
	Total Assets
23.70M	18.92M	31.40M	8.76M	2.60K
	Total Debt
0.00	0.00	0.00	0.00	3.77M
	Net Debt
-23.37M	-18.52M	-29.69M	-8.76M	3.76M
	Total Liabilities
17.98M	6.61M	2.72M	1.33M	6.81M
	Stockholders Equity
5.72M	12.32M	28.69M	7.43M	-6.81M
Cash Flow		Free Cash Flow
-28.32M	-18.96M	-10.67M	-3.73M	-218.44K
	Operating Cash Flow
-28.32M	-18.96M	-10.67M	-3.73M	-218.44K
	Investing Cash Flow
0.00	0.00	0.00	0.00	0.00
	Financing Cash Flow
33.17M	7.79M	31.60M	12.83M	100.00K

Reviva Pharmaceuticals Holdings Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.89
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RVPH, the sentiment is Negative. The current price of 0.89 is above the 20-day moving average (MA) of 0.73, below the 50-day MA of 0.99, and below the 200-day MA of 1.29, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 50.61 is Neutral, neither overbought nor oversold. The STOCH value of 83.96 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RVPH.

Reviva Pharmaceuticals Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$5.28B	3.75	-42.72%	2.86%	17.70%	2.03%
CNTB	49 Neutral	$45.47M	―	-58.89%	―	―	―
DYAI	46 Neutral	$36.26M	―	-139.16%	―	20.58%	15.90%
PEPG	42 Neutral	$51.37M	―	-79.26%	―	―	14.06%
OKYO	38 Underperform	$53.71M	―	0.00%	―	―	―
RVPH	28 Underperform	$41.60M	―	-916.17%	―	―	45.15%

Reviva Pharmaceuticals Holdings Corporate Events

Reviva Pharmaceuticals Approves Executive Compensation Changes

On February 13, 2025, Reviva Pharmaceuticals Holdings’ Compensation Committee approved several compensation arrangements for its executives, with retroactive base salary increases effective from January 1, 2025. Additionally, the committee set new bonus targets for 2025 and approved significant stock option grants, reflecting confidence in the leadership team and aligning their interests with shareholders.